About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT03984422

Application for Monitoring and Evaluation of Raynaud's Phenomenon

To evaluate the feasibility of using a smartphone application for monitoring and evaluation of Raynaud's Phenomenon.

Lead sponsor: University Hospital, Grenoble•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Matthieu Roustit, PharmD, PhD

CONTACT

+33476767856 mroustit@chu-grenoble.fr

Adeline PARIS, PharmD, PhD

CONTACT

+33476767383 aparis@chu-grenoble.fr

Sponsors

Lead Sponsor

University Hospital, Grenoble

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•primary or secondary Raynaud phenomenon clinically diagnosed by a physician
•Phone compatible with the application (most Android smartphones)
•Non-opposition of participation in the study
•Affiliation to the social security scheme or beneficiary of such a scheme

Exclusion Criteria

•Subject under administrative or judicial supervision
•Subject not speaking and not understanding French

Related studies

COMPLETEDPhase 2

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

NCT03867097 · Raynaud Phenomenon Secondary to Systemic Sclerosis

COMPLETEDPhase 2

Cold Challenge With C21 in RP

NCT04388176 · Raynaud Phenomenon, Systemic Sclerosis

Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon

NCT03972566 · CREST Syndrome, Calcinosis Cutis, and more

Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon

NCT03094910 · Raynaud Disease, Raynaud Phenomenon, and more

COMPLETEDEARLY Phase 1

Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

NCT03027674 · Raynaud Phenomenon Due to Trauma, Raynaud Disease, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 6, 2023Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment120

Start dateMar 2020

Last updatedDec 6, 2023

Condition

Raynaud Phenomenon

Locations shown

Chu Grenoble Alpes

Grenoble, Grenoble

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 6, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions